NAV 1800

Drug Profile

NAV 1800

Alternative Names: NAV-1800; RIGScan CR; RIGScan-CR49

Latest Information Update: 03 Feb 2016

Price : $50

At a glance

  • Originator Neoprobe
  • Developer Navidea Biopharmaceuticals
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Colorectal cancer

Most Recent Events

  • 03 Feb 2016 No recent reports on development identified - Phase-III for Colorectal cancer (Diagnosis, Metastatic disease) in USA (IV)
  • 26 Sep 2013 Phase-III clinical trials in Colorectal (diagnosis, metastatic disease) cancer in USA (IV)
  • 26 Sep 2013 Phase-III clinical trials in Diagnostic imaging in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top